



## CONTACTS

### **EpiCept Corporation:**

777 Old Saw Mill River Road  
Tarrytown, NY 10591  
Robert W. Cook  
(914) 606-3500  
[rcook@epicept.com](mailto:rcook@epicept.com)

### **Media:**

**Feinstein Kean Healthcare**  
Greg Kelley  
(617) 577-8110  
[gregory.kelley@fkhealth.com](mailto:gregory.kelley@fkhealth.com)

### **Investors:**

**Lippert/Heilshorn & Associates**  
Kim Sutton Golodetz  
(212) 838-3777  
[kgolodetz@lhai.com](mailto:kgolodetz@lhai.com)

or

Bruce Voss  
(310) 691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

## **EPICEPT CORPORATION TO PRESENT AT TWO UPCOMING INVESTOR CONFERENCES**

**TARRYTOWN, N.Y. – (October 27, 2008)** – EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Jack Talley, President and CEO, will be presenting at the 2008 BIOCOM Investor Conference on October 28, 2008 from 11:30-11:55 a.m. local time at the Hyatt Regency La Jolla in San Diego, California. Mr. Talley will also present at the Rodman & Renshaw Annual Global Investor Conference on November 10, 2008 from 10:20 – 10:45 a.m. local time at the New York Palace Hotel in New York.

Both presentations will be available live via webcast for 90 days thereafter. The webcasts can be accessed by visiting [www.epicept.com](http://www.epicept.com).

### **About EpiCept Corporation**

EpiCept is focused on unmet needs in the treatment of cancer and pain. The Company's broad portfolio of pharmaceutical product candidates includes Ceplene, a cytokine immunomodulator that recently received marketing authorization in Europe for the remission maintenance of AML patients, and several pain therapies in clinical development. In addition, EpiCept's ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

October 27, 2008

Page 2

### **Forward-Looking Statements**

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not be launched in Europe in the first quarter of 2009 or achieve significant commercial success, the risk that we are unable to find a suitable marketing partner for Ceplene on attractive terms, a timely basis or at all, the risk that any post-approval clinical study will not be successful, the risk that EpiCept will not be able to maintain its final regulatory approval or marketing authorization, the risk that Myriad's development of Azixa(TM) will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk that the development of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC2407 will not be successful, the risk that NP-1 or EPC2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risks associated with the adequacy of our existing cash resources, our need to raise additional financing to continue to meet our capital needs and our ability to continue as a going concern, the risks associated with our ability to continue to meet our obligations under our existing debt agreements or that we may default on our loans or that our lenders may declare the Company in default, the risk that we will not obtain approval to market any of our product candidates other than Ceplene(R), the risk that the Company's securities may be delisted by The Nasdaq Capital Market or the OMX Nordic Exchange, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings, which are available at [www.sec.gov](http://www.sec.gov) or at [www.epicept.com](http://www.epicept.com). You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

###

*\*Azixa is a registered trademark of Myriad Genetics, Inc.*

EPCT-GEN